Pentetic Acid

Pentetic Acid

SCHEMBL2819134

O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O.[CaH2].[NaH].[NaH].[NaH]

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.88
BLM P54132 2/20 0.88
PMP22 Q01453 2/20 0.88
KDM4E B2RXH2 2/20 0.88
ALOX15 P16050 2/20 0.88
LMNA P02545 1/20 0.88
CHRM2 P08172 1/20 0.88
ADRA2A P08913 1/20 0.88
TSHR P16473 1/20 0.88
DRD1 P21728 1/20 0.88
SLC6A2 P23975 1/20 0.88
SLC6A4 P31645 1/20 0.88
CYP2C19 P33261 1/20 0.88
ADRA1A P35348 1/20 0.88
DRD3 P35462 1/20 0.88
SLC6A3 Q01959 1/20 0.88
HRH3 Q9Y5N1 1/20 0.88
EYA2 O00167 1/20 0.82
APP P05067 1/20 0.82
ACE P12821 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Edetic Acid SCHEMBL531145 0.97 TDP1 (0.88) TDP1BLMPMP22KDM4EALOX15
Edetic Acid SCHEMBL42175 0.97 TDP1 (0.88) TDP1BLMPMP22KDM4EALOX15
Edetic Acid SCHEMBL769944 0.97 TDP1 (0.88) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL9130818 0.97 TDP1 (0.94) TDP1BLMPMP22KDM4EALOX15
Edetic Acid SCHEMBL531146 0.97 TDP1 (0.88) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL456025 0.97 TDP1 (0.94) TDP1BLMPMP22KDM4EALOX15
Edetic Acid SCHEMBL4533309 0.97 TDP1 (0.88) TDP1BLMPMP22KDM4EALOX15
Edetic Acid SCHEMBL1566615 0.97 TDP1 (0.88) TDP1BLMPMP22KDM4EALOX15
Edetic Acid SCHEMBL121502 0.97 TDP1 (0.88) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL18917020 0.94 TDP1 (0.88) TDP1BLMPMP22KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2148836-B1 METHOD FOR THE PREPARATION OF REACTIVE [18]F FLUORIDE TRASIS S A (BE) 2017-10-25 EP claimed
US-8641903-B2 Method for the preparation of reactive [18] F fluoride TRASIS S.A. (BE) 2014-02-04 US claimed
US-20100243972-A1 METHOD FOR THE PREPARATION OF REACTIVE [18] F FLUORIDE TRASIS S.A. (BE) 2010-09-30 US claimed
EP-2148836-A1 METHOD FOR THE PREPARATION OF REACTIVE Ý18¨F FLUORIDE Universite de Liege (BE) 2010-02-03 EP claimed
EP-1990310-A1 Method for the preparation of reactive 18F fluoride, and for the labeling of radiotracers, using a modified non-ionic solid support and without any evaporation step Trasis S.A. (BE) 2008-11-12 EP claimed
WO-2008128306-A1 METHOD FOR THE PREPARATION OF REACTIVE [18] F FLUORIDE TRASIS S.A. (BE) 2008-10-30 WO claimed
US-11384106-B2 Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers EMORY UNIVERSITY (US) 2022-07-12 US disclosed
US-20200231615-A1 Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers UNIV EMORY (US) 2020-07-23 US disclosed
US-10633404-B2 Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers EMORY UNIVERSITY (US) 2020-04-28 US disclosed
US-10434195-B2 Methylsulfonamide derivatives and uses related thereto EMORY UNIVERSITY (US) 2019-10-08 US disclosed
US-20180057517-A1 Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers UNIV EMORY (US) 2018-03-01 US disclosed
EP-2148836-B1 METHOD FOR THE PREPARATION OF REACTIVE [18]F FLUORIDE TRASIS S A (BE) 2017-10-25 EP disclosed
US-8641903-B2 Method for the preparation of reactive [18] F fluoride TRASIS S.A. (BE) 2014-02-04 US disclosed
WO-2008128306-A1 METHOD FOR THE PREPARATION OF REACTIVE [18] F FLUORIDE TRASIS S.A. (BE) 2008-10-30 WO disclosed
US-6022966-A CONJUGATE COMPRISES A DOTA CHELATE COMPONENT, A BIOTIN COMPONENT AND A LINKER COMPONENT RESISTANT TO BIOTINIDASE CLEAVAGE NEORX CORPORATION (US) 2000-02-08 US disclosed
EP-0736035-A4 PRETARGETING METHODS AND COMPOUNDS NEORX CORP (US) 1999-09-01 EP disclosed
US-5847121-A Production of nitro-benzyl-dota via direct peptide cyclization NEORX CORPORATION (US) 1998-12-08 US disclosed
EP-0736035-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1996-10-09 EP disclosed
US-5541287-A DIAGNOSIS USING CYCLIC TRIPEPTIDES WITH NITROBENZYL 1,4,7,10-TETRAAZACYCLODODECANE-N,N*,N**,N***TETRAACETIC ACID BIOTIN CONJUGATE FORMED BY ALKYLATION AND MULTISTAGE PROCESS NEORX CORPORATION (US) 1996-07-30 US disclosed
WO-1995015335-A2 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231615-A1 Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers SLC16A8, S100A8, FGF23 TDP1 4416/4885BLM 2066/4885PMP22 2847/4885
US-20180057517-A1 Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers SLC16A8, S100A8, FGF23 TDP1 4416/4885BLM 2066/4885PMP22 2847/4885
US-10434195-B2 Methylsulfonamide derivatives and uses related thereto CXCR4, CXCL12, CXCR2 TDP1 2182/4885BLM 3641/4885PMP22 1350/4885
US-10633404-B2 Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers SLC16A8, S100A8, FGF23 TDP1 4416/4885BLM 2066/4885PMP22 2847/4885
US-11384106-B2 Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers SLC16A8, S100A8, FGF23 TDP1 4416/4885BLM 2066/4885PMP22 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.